Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30877285 | 0.90 | HTR2A (0.38) | HTR1DHTR2ASLC6A4HTR1AHTR2C | |
| SCHEMBL29206361 | 0.90 | HTR2A (0.38) | HTR1DHTR2ASLC6A4HTR1AHTR2C | |
| SCHEMBL29206518 | 0.87 | GPR84 (0.55) | HTR2ASLC6A4HTR1AGPR84MPO | |
| SCHEMBL31158585 | 0.87 | GPR84 (0.55) | HTR2ASLC6A4HTR1AGPR84MPO | |
| SCHEMBL29206462 | 0.86 | HTR2A (0.43) | HTR1DHTR2ASLC6A4HTR1AHTR2C | |
| SCHEMBL30877245 | 0.86 | HTR2A (0.43) | HTR1DHTR2ASLC6A4HTR1AHTR2C | |
| SCHEMBL29206396 | 0.85 | HTR2A (0.54) | HTR1DHTR2ASLC6A4HTR1AHTR2C | |
| SCHEMBL29206430 | 0.85 | HTR1D (0.59) | HTR1DHTR2ASLC6A4HTR1AHTR2C | |
| SCHEMBL29206385 | 0.82 | HTR1A (0.57) | HTR1DHTR2ASLC6A4HTR1AHTR2C | |
| SCHEMBL30877232 | 0.82 | HTR2A (0.42) | HTR1DHTR2ASLC6A4HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957211-A | Fluorinated tryptamine compounds, analogs thereof, and methods of use thereof | 圣约瑟夫大学 | 2024-04-30 | — | — | CN | claimed |
| US-20240286998-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | SAINT JOSEPH'S UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| CN-117957211-A | Fluorinated tryptamine compounds, analogs thereof, and methods of use thereof | 圣约瑟夫大学 | 2024-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240286998-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | TPH2, TPH1, HNMT | HTR1D 27/4885HTR2A 4/4885SLC6A4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.